Phio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Phio Pharmaceuticals's earnings have been declining at an average annual rate of -10.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 97% per year.
Key information
-10.7%
Earnings growth rate
80.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -97.0% |
| Return on equity | -140.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Phio Pharmaceuticals appoints interim executive chairman
Sep 29Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12
Aug 11Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?
Apr 11
Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer
Nov 09Revenue & Expenses BreakdownBeta
How Phio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -11 | 4 | 0 |
| 30 Sep 23 | 0 | -12 | 5 | 0 |
| 30 Jun 23 | 0 | -12 | 5 | 0 |
| 31 Mar 23 | 0 | -12 | 5 | 0 |
| 31 Dec 22 | 0 | -11 | 4 | 0 |
| 30 Sep 22 | 0 | -12 | 5 | 0 |
| 30 Jun 22 | 0 | -12 | 5 | -4 |
| 31 Mar 22 | 0 | -13 | 4 | 0 |
| 31 Dec 21 | 0 | -13 | 5 | 0 |
| 30 Sep 21 | 0 | -12 | 5 | 0 |
| 30 Jun 21 | 0 | -11 | 5 | 4 |
| 31 Mar 21 | 0 | -10 | 5 | 0 |
| 31 Dec 20 | 0 | -9 | 5 | 0 |
| 30 Sep 20 | 0 | -9 | 5 | 0 |
| 30 Jun 20 | 0 | -9 | 5 | 0 |
| 31 Mar 20 | 0 | -9 | 5 | 0 |
| 31 Dec 19 | 0 | -9 | 5 | 0 |
| 30 Sep 19 | 0 | -8 | 4 | 0 |
| 30 Jun 19 | 0 | -7 | 3 | 0 |
| 31 Mar 19 | 0 | -7 | 3 | 0 |
| 31 Dec 18 | 0 | -7 | 3 | 0 |
| 30 Sep 18 | 0 | -8 | 3 | 0 |
| 30 Jun 18 | 0 | -9 | 3 | 0 |
| 31 Mar 18 | 0 | -9 | 4 | 0 |
| 31 Dec 17 | 0 | -12 | 4 | 0 |
| 30 Sep 17 | 0 | -15 | 4 | 0 |
| 30 Jun 17 | 0 | -15 | 4 | 0 |
| 31 Mar 17 | 0 | -14 | 4 | 0 |
| 31 Dec 16 | 0 | -11 | 4 | 0 |
| 30 Sep 16 | 0 | -9 | 3 | 0 |
| 30 Jun 16 | 0 | -10 | 4 | 0 |
| 31 Mar 16 | 0 | -10 | 3 | 0 |
| 31 Dec 15 | 0 | -10 | 3 | 0 |
| 30 Sep 15 | 0 | -11 | 3 | 0 |
| 30 Jun 15 | 0 | -11 | 3 | 0 |
| 31 Mar 15 | 0 | -12 | 3 | 0 |
| 31 Dec 14 | 0 | -13 | 3 | 0 |
| 30 Sep 14 | 0 | -14 | 4 | 0 |
| 30 Jun 14 | 0 | -14 | 4 | 0 |
| 31 Mar 14 | 0 | -16 | 4 | 0 |
| 31 Dec 13 | 0 | -30 | 4 | 0 |
| 30 Sep 13 | 0 | -28 | 3 | 0 |
| 30 Jun 13 | 0 | -28 | 3 | 0 |
Quality Earnings: PHIO is currently unprofitable.
Growing Profit Margin: PHIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHIO is unprofitable, and losses have increased over the past 5 years at a rate of 10.7% per year.
Accelerating Growth: Unable to compare PHIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: PHIO has a negative Return on Equity (-140.05%), as it is currently unprofitable.